Healthcare Litigation Finance: Malpractice, Pharma, and Device Portfolios

How funders evaluate medical malpractice, pharmaceutical, and device claims and the data considerations involved.

Healthcare litigation finance spans a range of claims arising from medical care and products, including medical malpractice, pharmaceutical injury, and medical device defect litigation. These matters can involve substantial damages, particularly where serious or permanent injury is alleged, and they require specialized medical and scientific expertise to evaluate. The category includes both individual high-value cases and large mass tort inventories, each with distinct funding considerations.

Medical malpractice claims turn on proving that a healthcare provider breached the applicable standard of care and that the breach caused the patient's injury. These cases require credible medical experts on both standard of care and causation, and outcomes vary significantly by jurisdiction, given differences in damages caps, expert requirements, and jury attitudes. Funders evaluate the strength of the standard-of-care and causation evidence, the severity of the injury and resulting damages, and the jurisdiction-specific factors that shape recovery.

Pharmaceutical and medical device litigation often proceeds as mass torts through MDLs, where thousands of plaintiffs allege injury from a drug or device. These matters depend heavily on general causation, whether the product can cause the alleged harm, which is established through epidemiology and scientific evidence and tested in early rulings and bellwether trials. Funders evaluate the strength of the science, the procedural posture of the MDL, and the defendant's settlement history, treating these as portfolio investments rather than individual cases.

Data sensitivity is a particular consideration in healthcare litigation funding. Evaluating these claims involves medical records and protected health information, and funders must handle such information consistent with privacy requirements including HIPAA. Underwriting processes are structured to assess the strength of claims while protecting confidential medical information, and funding agreements address the handling of sensitive data. This adds an operational dimension absent from many other litigation categories.

Criterica Capital funds healthcare litigation, evaluating malpractice, pharmaceutical, and device claims against outcome data drawn from 106M+ court records while handling medical information consistent with privacy requirements. This grounds our assessment of these specialized matters in observed outcomes. Firms pursuing healthcare claims and inventories can contact our institutional team to discuss funding.

Discuss your matter with our institutional team.